257 related articles for article (PubMed ID: 27596051)
1. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.
Xu J; Xiong G; Cao Z; Huang H; Wang T; You L; Zhou L; Zheng L; Hu Y; Zhang T; Zhao Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):133. PubMed ID: 27596051
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
3. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X
Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
Liang C; Yu XJ; Guo XZ; Sun MH; Wang Z; Song Y; Ni QX; Li HY; Mukaida N; Li YY
Oncotarget; 2015 Jun; 6(16):14440-55. PubMed ID: 25971209
[TBL] [Abstract][Full Text] [Related]
6. Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells.
Zhang Z; Gao S; Xu Y; Zhao C
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200805
[TBL] [Abstract][Full Text] [Related]
7. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Torres C; Linares A; Alejandre MJ; Palomino-Morales RJ; Delgado JR; Perales S
Pancreas; 2016 Feb; 45(2):269-80. PubMed ID: 26495790
[TBL] [Abstract][Full Text] [Related]
8. ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer.
Jun I; Park HS; Piao H; Han JW; An MJ; Yun BG; Zhang X; Cha YH; Shin YK; Yook JI; Jung J; Gee HY; Park JS; Yoon DS; Jeung HC; Lee MG
Br J Cancer; 2017 Dec; 117(12):1798-1809. PubMed ID: 29024940
[TBL] [Abstract][Full Text] [Related]
9. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
10. MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.
Chang W; Liu M; Xu J; Fu H; Zhou B; Yuan T; Chen P
Tumour Biol; 2016 Nov; 37(11):14813-14824. PubMed ID: 27638830
[TBL] [Abstract][Full Text] [Related]
11. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
12. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
13. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
[TBL] [Abstract][Full Text] [Related]
14. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
15. WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.
Wei W; Sun HH; Li N; Li HY; Li X; Li Q; Shen XH
Hepatobiliary Pancreat Dis Int; 2014 Oct; 13(5):529-38. PubMed ID: 25308364
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
17. Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Xiao Q; Zheng F; Tang Q; Wu JJ; Xie J; Huang HD; Yang XB; Hann SS
Cell Physiol Biochem; 2018; 49(4):1615-1632. PubMed ID: 30223276
[TBL] [Abstract][Full Text] [Related]
18. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract][Full Text] [Related]
20. sATP‑binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells.
Wu S; Zhang X; Dong M; Yang Z; Zhang M; Chen Q
Oncol Rep; 2020 Oct; 44(4):1467-1478. PubMed ID: 32945520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
